CSPG4 and gastrointestinal stromal tumor: We showed that expression of CSPG4, a new potential target for immune therapy, notably specific CAR-CIKs, is heterogeneous in GIST clinical samples and that high expression is associated independently with DFS and with an immune landscape favorable to induce strong cytotoxic immune response after NK cell stimulation.